125,000 Shares in Caris Life Sciences, Inc. $CAI Purchased by E. Ohman J or Asset Management AB

E. Ohman J or Asset Management AB purchased a new position in shares of Caris Life Sciences, Inc. (NASDAQ:CAI) in the 3rd quarter, Holdings Channel.com reports. The fund purchased 125,000 shares of the company’s stock, valued at approximately $3,829,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. PointState Capital LP purchased a new stake in Caris Life Sciences during the 2nd quarter worth $121,690,000. BlackRock Inc. acquired a new stake in Caris Life Sciences in the second quarter valued at $98,666,000. Canada Pension Plan Investment Board acquired a new position in Caris Life Sciences during the 2nd quarter worth $24,502,000. Bank of America Corp DE acquired a new stake in shares of Caris Life Sciences in the 2nd quarter valued at about $21,395,000. Finally, Amundi lifted its position in shares of Caris Life Sciences by 5,709.5% during the second quarter. Amundi now owns 1,218,364 shares of the company’s stock worth $21,711,000 after purchasing an additional 1,197,392 shares during the last quarter.

Insider Transactions at Caris Life Sciences

In other news, President David Spetzler sold 478,000 shares of the stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $24.86, for a total value of $11,883,080.00. Following the completion of the transaction, the president owned 1,052,083 shares in the company, valued at approximately $26,154,783.38. This represents a 31.24% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Russel Denton sold 7,500 shares of the company’s stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $31.82, for a total transaction of $238,650.00. Following the completion of the sale, the insider directly owned 174,855 shares in the company, valued at approximately $5,563,886.10. The trade was a 4.11% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 1,004,712 shares of company stock worth $27,205,419. 50.00% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

CAI has been the subject of a number of research reports. Canaccord Genuity Group lifted their price objective on shares of Caris Life Sciences from $22.00 to $30.00 and gave the stock a “hold” rating in a report on Monday. Evercore restated an “outperform” rating and set a $26.00 price objective on shares of Caris Life Sciences in a research note on Thursday, August 6th. BTIG Research increased their price objective on shares of Caris Life Sciences from $32.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. UBS Group started coverage on shares of Caris Life Sciences in a research note on Wednesday, September 9th. They issued a “neutral” rating and a $28.00 price target on the stock. Finally, Wall Street Zen raised Caris Life Sciences from a “sell” rating to a “hold” rating in a research note on Sunday, August 16th. Eight equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $28.55.

Caris Life Sciences Stock Performance

NASDAQ:CAI opened at $31.71 on Friday. The firm has a market capitalization of $8.96 billion, a PE ratio of 88.08 and a beta of 0.86. The company has a current ratio of 5.53, a quick ratio of 4.88 and a debt-to-equity ratio of 0.66. Caris Life Sciences, Inc. has a 1 year low of $14.19 and a 1 year high of $33.13. The firm’s fifty day simple moving average is $27.82 and its 200 day simple moving average is $21.31.

About Caris Life Sciences

Caris Life Sciences is a biotechnology and precision-medicine company that uses molecular profiling and artificial intelligence to support cancer diagnosis, treatment selection and drug development. The company analyzes tumor and blood samples to identify genomic, molecular and immune characteristics that may help physicians better understand a patient’s disease and select targeted therapies.

Its offerings include comprehensive tumor profiling, liquid-biopsy testing and data-driven clinical decision-support tools.